Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Payables (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Payables for 4 consecutive years, with $7.6 million as the latest value for Q4 2025.

  • Quarterly Payables rose 6.15% to $7.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.6 million through Dec 2025, up 6.15% year-over-year, with the annual reading at $7.6 million for FY2025, 6.15% up from the prior year.
  • Payables for Q4 2025 was $7.6 million at Centessa Pharmaceuticals, down from $8.7 million in the prior quarter.
  • The five-year high for Payables was $14.4 million in Q1 2023, with the low at $5.1 million in Q1 2025.
  • Average Payables over 4 years is $8.9 million, with a median of $7.9 million recorded in 2022.
  • The sharpest move saw Payables soared 114.8% in 2023, then crashed 52.01% in 2024.
  • Over 4 years, Payables stood at $13.8 million in 2022, then dropped by 14.61% to $11.8 million in 2023, then plummeted by 39.54% to $7.1 million in 2024, then grew by 6.15% to $7.6 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $7.6 million, $8.7 million, and $5.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.